Shots:
- Welcome to the October edition of Know Your Investor, spotlighting leading investors shaping the future of healthcare and life sciences
- This month, we feature Google Ventures (GV), the venture capital arm of Alphabet. GV actively invests across seed to growth-stage companies, spanning sectors such as software, internet, healthcare, life sciences, and artificial intelligence
- For a curated report on a specific investor or venture capital firm, connect with us at connect@pharmashots.com
Founded in 2009 by Bill Maris, Google Ventures (GV) operates as the venture capital arm of Alphabet. Headquartered in San Francisco, with offices in New York, Cambridge, and London, GV made its debut investments in Silver Spring Networks and Adimab. Its operating partners support portfolio companies across talent, engineering, equity, diversity & inclusion, and design, while also enabling strategic connections with Google.
GV now manages over $10B in assets, with 400 active portfolios, 80 IPOs, and more than 200 M&A transactions. In 2024, GV participated in eight investment rounds comprising Seed, Private, and Series A-F & beyond. Key additions to its portfolio include:
- Areteia Therapeutics Inc.
- Trace Neuroscience Inc.
- Cardurion Pharmaceuticals Inc
- Infinitus Systems Inc.
The Firm’s largest single investment in 2024 remained in Curie.Bio worth $900M
GV with a wide portfolio invests in companies like the internet, software, hardware, life science, healthcare, artificial intelligence, transportation, cyber security, and agriculture. In life sciences, GV invests in therapeutics, diagnostics, medical devices, and health tech startups.
Therapeutic Areas of Focus (2024):
- Autoimmune
- Oncology
- Cardiovascular
- Dermatology
- Endocrine/Metabolic
- Urology
- Infectious Disease
- Musculoskeletal
- Gastrointestinal
- Neurologic
- Pulmonology
Technological Focus (2024):
- Small molecules
- Digital Health
- Peptides
- Genomics
- Gene therapies
- Proteins
- Devices
- AI/ML
- Diagnostics
In 2024:
- Total Companies Invested In: 31
- Series A: 40.62% of investments
- Series B: 28.12% of investments
Key Investments in 2024:
- $900M Series A – Curie.Bio
- $425M Series A – Areteia Therapeutics
- $260M Series B – Cardurion Pharmaceutical
Quarterly Investments in 2024:
- Q1: 10 investments worth $0.89B
- Q2: 6 investments worth $1.43B
- Q3: 4 investments worth $0.36B
- Q4: 12 investments worth $0.82B
The table below depicts the top 5 out of the 32 investments made by Google Ventures:
Note: (For a complete report, reach out to us at connect@pharmashots.com with the subject line “Google Ventures” or for early access to complete data for future reports and analysis, register here: https://forms.office.com/r/VwFu6aUm80)
Related Post: Know Your Investor (June Edition): Google Ventures
